Runny nose; sneezing; itchy nose, throat, or eyes; and congestion: An
estimated 20% to 25% of the Canadian population suffer from allergic
KIRKLAND, QC, May 15, 2014 /CNW Telbec/ - A new treatment option is now
available for Canadian allergic rhinitis sufferers. RAGWITEK™
(Standardized Allergen Extract, Short Ragweed (Ambrosia artemisiifolia) Sublingual Tablet) is an immunotherapy treatment to help manage
ragweed allergies. It is indicated for reducing the signs and symptoms
of moderate to severe seasonal short ragweed pollen induced allergic
rhinitis, with or without conjunctivitis, in adults confirmed by
clinically relevant symptoms for at least two pollen seasons and a
positive skin prick test and/or a positive titre to Ambrosia artemisiifolia specific IgE, and who have responded inadequately, or are intolerant to
"Immunotherapy treatment retrains the immune system. By administering a
standardized dose of an allergen we can accustom the body to not react
in an allergic way to allergens such as ragweed pollen", says Dr. Paul
Keith, Allergist / Immunologist, Associate Professor, Division of
Clinical Immunology and Allergy, Department of Medicine, McMaster
University. "Not only have these sublingual immunotherapy tablets
demonstrated excellent safety and efficacy profiles, they also
represent a convenient choice of treatment for our patients".
Efficacy demonstrated during the first ragweed pollen season
For optimal results, the dosing should be initiated at least twelve
weeks before the ragweed pollen season and maintained throughout this
"It is recommended to start this ragweed sublingual immunotherapy
treatment at least three months prior to the ragweed season and
maintain daily dosing throughout the season. The patient has to place
the tablet under the tongue, where it will dissolve in seconds, and
after the first dose taken in the doctor's office, this can be done at
home", concludes Dr. Keith.
RAGWITEK™ has been approved for use in adults with efficacy and safety
data demonstrated in two clinical trials which involved 1349 patients
18 to 50 years of age with short ragweed pollen-induced
With this new treatment option, Merck Canada affirms its longtime
commitment to developing respiratory products that provide physicians
with a wide range of treatment options to help their patients suffering
About allergies and allergic rhinitis
Caused by the immune system over reacting to a normally harmless
substance called an allergen, allergic rhinitis sufferers can
experience symptoms such as sneezing, nasal congestion, a runny nose,
itchiness in the nose, throat, eyes and ears.5
Approximately 20% to 25% of the Canadian population suffers from
allergic rhinitis, an inflammatory disease of the nasal mucous
membranes whose prevalence is increasing worldwide.1 Often starting in childhood and persisting into adult life,6 allergic rhinitis can have an impact on the sufferers' social life,
school performance, and work productivity.7
Today's Merck is a global healthcare leader working to help the world be
well. Merck is known as MSD outside the United States and Canada.
Through our prescription medicines, vaccines, biologic therapies, and
consumer care and animal health products, we work with customers and
operate in more than 140 countries to deliver innovative health
solutions. We also demonstrate our commitment to increasing access to
healthcare through far-reaching policies, programs and partnerships.
For more information about our operations in Canada, visit www.merck.ca.
Forward Looking Statement
This website includes "forward-looking statements" within the meaning of
the safe harbor provisions of the United States Private Securities
Litigation Reform Act of 1995. These statements are based upon the
current beliefs and expectations of Merck's management and are subject
to significant risks and uncertainties. There can be no guarantees with
respect to pipeline products that the products will receive the
necessary regulatory approvals or that they will prove to be
commercially successful. If underlying assumptions prove inaccurate or
risks or uncertainties materialize, actual results may differ
materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry
conditions and competition; general economic factors, including
interest rate and currency exchange rate fluctuations; the impact of
pharmaceutical industry regulation and health care legislation in the
United States and internationally; global trends toward health care
cost containment; technological advances, new products and patents
attained by competitors; challenges inherent in new product
development, including obtaining regulatory approval; Merck's ability
to accurately predict future market conditions; manufacturing
difficulties or delays; financial instability of international
economies and sovereign risk; dependence on the effectiveness of
Merck's patents and other protections for innovative products; and the
exposure to litigation, including patent litigation, and/or regulatory
Merck undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or
otherwise. Additional factors that could cause results to differ
materially from those described in the forward-looking statements can
be found in Merck's 2012 Annual Report on Form 10-K and the company's
other filings with the Securities and Exchange Commission (SEC)
available at the SEC's Internet site (www.sec.gov).
The news release is available at www.cnw.ca.
PHOTO and caption available here.
1 Keith, P., Desrosiers, M. et al, 2012. The Burden of Allergic Rhinitis
(AR) in Canada: Perspectives of Physicians and Patients, Allergy, Asthma and Clinical Immunology [Online] Available at: www.aacijournal.com/content/8/1/7 [Accessed 2014-04-23].
2 RAGWITEK Product Monograph, Merck Canada Inc., April 23, 2014. Page 3
3 RAGWITEK Product Monograph, Merck Canada Inc., April 23, 2014. Page 12
4 RAGWITEK Product Monograph, Merck Canada Inc., April 23, 2014. Page 7
5 American Academy of Allergy Asthma & Immunology, 2013. Allergic Reactions: Tips to Remember [Online] Available at: www.aaaai.org/patients/publicedmat/tips/whatisallergicreaction.stm [Accessed 2014-04-23].
6 Allergy/Asthma Information Association, 2008. Allergic Rhinitis [Online] Available at: www.aaia.ca/en/allergic_rhinitis.htm [Accessed 2014-04-23].
7 Brozek, J. L., Bousquet, J. et al. Allergic Rhinitis and its Impact on
Asthma (ARIA) Guidelines: 2010 Revision. Journal of Allergy & Clinical Immunology Vol. 126(3), pp. 466-476
For further information: